Literature DB >> 6267940

Antibody responses to varicella-zoster virus and the role of antibody in host defense.

A A Gershon, S P Steinberg.   

Abstract

Antibody titers to varicella-zoster (VZ) virus in persons aged 1-85 years were measured. Through age 50, the percent of seropostitive individuals continued to rise. There was no fall in geometric mean titer with aging, and there may have been an increase in VZ antibody titer in older persons. Thus, a fall in VZ antibody with increasing age does not seem likely to account for the increased incidence of zoster in the elderly. Similarly, immunocompromised patients who are more likely to develop zoster than normals did not have lower VZ antibody titers than normal persons. Finally, immunocompromised persons with disseminated zoster had antibody titers that were somewhat higher that those of immunocompromised persons with localized zoster. It appears that humoral immunity has little or no influence on either the development or the course of herpes zoster.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6267940     DOI: 10.1097/00000441-198107000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

1.  Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins.

Authors:  M Ito; T Ihara; C Grose; S Starr
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

2.  Impact and costs of varicella prevention in a university hospital.

Authors:  D J Weber; W A Rutala; C Parham
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

Review 3.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

4.  The seroprevalence of varicella zoster antibodies in Behçet's and other skin diseases.

Authors:  Sedat Akdeniz; Mehmet Harman; Selahattin Atmaca; Nezahat Akpolat
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

5.  Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection.

Authors:  Michael N Oxman; Anne A Gershon; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-09       Impact factor: 3.641

6.  Social epidemiology of chickenpox in two British national cohorts.

Authors:  J I Pollock; J Golding
Journal:  J Epidemiol Community Health       Date:  1993-08       Impact factor: 3.710

7.  Age and immune status of rhesus macaques impact simian varicella virus gene expression in sensory ganglia.

Authors:  Christine Meyer; Jesse Dewane; Amelia Kerns; Kristen Haberthur; Alex Barron; Byung Park; Ilhem Messaoudi
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

8.  The epidemiology of varicella-zoster virus infections: a mathematical model.

Authors:  G P Garnett; B T Grenfell
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

9.  Posterior Ischemic Optic Neuropathy following Herpes Zoster Ophthalmicus.

Authors:  Mohammad Pakravan; Hamid Ahmadieh; Amir-Reza Kaharkaboudi
Journal:  J Ophthalmic Vis Res       Date:  2009-01

10.  Shingles Immunity and Health Functioning in the Elderly: Tai Chi Chih as a Behavioral Treatment.

Authors:  Michael Irwin; Jennifer Pike; Michael Oxman
Journal:  Evid Based Complement Alternat Med       Date:  2004-12-01       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.